MarketInOut Stock Screener Log In | Sign Up
 

Nautilus Biotechnology Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/09/2026
Nautilus Biotechnology Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization301.59 mln
Float73.83 mln
Earnings Date11/03/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

3.83
Transformational upside

Relative Strength

100 / 100
Top performer

Debt / Equity

0.21
Very low leverage

Pre-Tax Margin

-29,748%
Severely loss-making

ROE

-36.10
Deeply negative

Business Description

Founded in 2016 and based in Seattle, Washington, Nautilus Biotechnology is an early-stage life sciences company building a technology platform designed to measure and analyze proteins at a highly detailed level. Its core product, the Nautilus Voyager Platform, combines specialized instruments, chemical reagents, and software to identify and quantify proteins found in biological samples. The company has established research partnerships with leading institutions including Genentech, Cornell University, and the Michael J. Fox Foundation to advance its work.

Key Fundamentals

EPS-0.45
ROE-36.10
RPS0.00
ROIC-77.98
ROA-29.86
EBITDA, mln-50.55
EV / EBITDA-2.46
EV / EBIT-2.20
Revenue, mln0.19
EV / Revenue654

Quote Details

Last 2.25
Change 0.43 (23.63%)
Open 1.93
Volume 19,401,558
Turnover 43,653,504
Average Volume 6,989,946

Financial Ratios

Pre-Tax Profit Margin-29,748
Leverage Ratio1.25
Current Ratio10.14
Price / Book1.38
Price / Tangible Book1.38
Debt / Equity0.21
Price / Sales1,420

Financial Strength

Altman Z-Score-0.44
Piotroski F-Score 3 / 9
1-Year Target Price3.83
Short Ratio4.44
Short % of Float6.52

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 14.8% 98 / 100   
1 Month 127% 100 / 100   
2 Months 30.81% 95 / 100   
6 Months -23.73% 19 / 100   
1 Year 149% 98 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us